Skip to content

Harm-reduction information only — not medical advice. In crisis or experiencing adverse effects, contact a healthcare professional or your local emergency services immediately.

AnabolicDex logo AnabolicDex
Search (no-JS fallback)
Peptides Hormone SupportMuscle BuildingWeight Loss

Tesamorelin

Egrifta

N-terminally stabilized GHRH analog approved to reduce excess visceral fat in HIV lipodystrophy.

🚧 Expanded guide coming soon. This compound has PK data and a source — a full overview, mechanism, and dosing guide is pending editorial review.

Pharmacokinetic summary

Model tier
Simple (t½ + F, Tmax estimated)
Half-life
0.0 days
Bioavailability
50%
Typical dose
1–2 mg

Related compounds

CJC-1295 with DAC

Long-acting GHRH analog with a drug-affinity complex that extends half-life to ~6–8 days; weekly dosing.

CJC-1295 without DAC (Modified GRF 1-29)

Short-acting GHRH analog (~30 min half-life) usually paired with a GHRP for pulsatile GH release.

Sermorelin

Bioidentical GHRH fragment used diagnostically and off-label to stimulate endogenous growth hormone.

Protocols featuring Tesamorelin

Tesamorelin (Visceral Fat)

GHRH analog approved for HIV-associated lipodystrophy. 2mg daily subcutaneous for visceral fat reduction — the documented clinical dose, typically run 12–26 weeks.

Comments

Loading comments…